Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: A meta-analysis of clinical trials

Diabetes, Obesity and Metabolism

Volumn 13, Issue 11, 2011, Pages 972-981

  Wang, Y ^a   Li, L ^a   Yang, M ^a   Liu, H ^b   Boden, G ^c   Yang, G ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; GLP 1; Insulin; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

ACUTE KIDNEY FAILURE; BODY MASS; CEREBROVASCULAR ACCIDENT; COCHRANE LIBRARY; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DIABETIC PATIENT; DIET RESTRICTION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; EMBASE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPESTHESIA; HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THORAX PAIN; WEIGHT REDUCTION;

EID: 80053401330     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01436.x     Document Type: Review

References (38)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
2. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009; 122 (6 Suppl): S37-50.
3. Nathan DM, Buse JB, Davidson MB, American Diabetes Association, European Association for Study of Diabetes, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
5. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity, application to type 2 diabetes. Diabetes Care 1997; 20: 1744-1766.
6. Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004; 47: 357-366.
7. Barnett A. Exenatide. Expert Opin Pharmacother 2007; 8: 2593-2608.
8. Edavalath M, Stephens JW. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Prefer Adherence 2010; 4: 61-68.
9. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
10. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354: 1896-1900.
11. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-773.
12. Heine RJ, Van Gaal LF, Johns D et al. Exenacide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
13. Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259-267.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
15. Feinstein AR. Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia: WB Saunders Co, 1985.
16. Begg C. Publication bias. In: Cooper H, Hughes L eds. The Handbook of Research Synthesis. New York: Russell Sage Foundation, 1994; 399-409.
17. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-2348.
18. Bergenstal R, Lewin A, Bailey T et al. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009; 25: 65-75.
19. Bunck MC, Diamant M, Corner A et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-768.
20. Davies M, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11: 1153-1162.
21. Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomized trial. Lancet 2010; 375: 2234-2243.
22. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met +SU): A randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
23. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 2003; 26: 3080-3086.
24. Yki-Jarvinen H, Juurinen L, Alvarsson M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369.
25. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007; 30: 2767-2772.
26. Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25: 358-363.
27. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003; 22: 331-339.
28. Henry RR, Ratner RE, Stonehouse AH et al. Exenatide maintained glycemic control with associated weight reduction over two years in patients with type 2 diabetes. Diabetes 2006; 55: A116.
29. van Genugten RE, van Raalte DH, Diamant M. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract 2009; 86: S26-34.
30. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009; 26: 416-424.
31. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009; 122: S37-50.
32. Pinkney J, Fox T, Ranganath L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manage 2010; 6: 401-411.
33. Raskin P, Mohan A. Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial). Expert Opin Pharmacother 2010; 11: 2269-2271.
34. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin: a 26-week, randomized, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
35. Tzefos M, Olin JL. Glucagon-like peptide-1 analogue and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann Pharmacother 2010; 44: 1294-1300.
36. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-112.
37. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010; 103: 687-694.
38. Arnolds S, Dellweg S, Clair J et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010; 33: 1509-1515.